NEW YORK — Reduction of progressive ellipsoid zone attenuation through the use of subcutaneous elamipretide may correlate with visual function improvement in geographic atrophy, according to a study presented here.
“It is likely that we are on the verge of the first approved therapies for dry [age-related macular degermation], with complement inhibitors showing us we can slow the progression of geographic atrophy,” Jeffrey S. Heier, MD, FASRS, said at the American Society of Retina Specialists annual meeting. “As exciting as these advances are, we’re seeing that